SG11201408074VA - Substituted picolinamide kinase inhibitors - Google Patents

Substituted picolinamide kinase inhibitors

Info

Publication number
SG11201408074VA
SG11201408074VA SG11201408074VA SG11201408074VA SG11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA SG 11201408074V A SG11201408074V A SG 11201408074VA
Authority
SG
Singapore
Prior art keywords
california
international
avenue
methods
picolinamide
Prior art date
Application number
SG11201408074VA
Inventor
Yonghong Song
Qing Xu
Arvinder Sran
Shawn M Bauer
Zhaozhong J Jia
Brian Kane
Anjali Pandey
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of SG11201408074VA publication Critical patent/SG11201408074VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2013 (27.12.2013) WIPOIPCT (10) International Publication Number WO 2013/192046 A2 (51) International Patent Classification: A61K31/4709 (2006.01) C07D 401/02 (2006.01) (21) International Application Number: (74) Agents: HOPKINS, Mark H. et al.; Kilpatrick Townsend & Stockton LLP, Eighth Floor, Two Embarcadero Center, San Francisco, California 94111 (US). (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/663,510 13/841,867 22 June 2012 (22.06.2012) 15 March 2013 (15.03.2013) (71) Applicant: PORTOLA PHARMACEUTICALS, INC. [US/US]; 270 E. Grand Avenue, Suite 22, South San Fran­ cisco, California 94080 (US). (72) Inventors: SONG, Yonghong; 860 Polaris Avenue, Foster City, California 94404 (US). XU, Qing; 836 Polaris Aven­ ue, Foster City, California 94404 (US). SRAN, Arvinder; 37623 Central Cove Court, Fremont, California 94536 (US). BAUER, Shawn M.; 181 Beachview Avenue, Paci- fica, California 94044 (US). JIA, Zhaozhong J.; 3416 Leafwood Court, San Mateo, California 94403 (US). KANE, Brian; 5964 Merriewood Drive, Oakland, Califor­ nia 94611 (US). PANDEY, Anjali; 4506 Amiens Avenue, Fremont, California 94555 (US). PCT/US2013/045987 (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 14 June 2013 (14.06.2013) English English US US (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ o CJ as i-H o CJ (54) Title: SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS (57) Abstract: Provided are picolinamide compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
SG11201408074VA 2012-06-22 2013-06-14 Substituted picolinamide kinase inhibitors SG11201408074VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663510P 2012-06-22 2012-06-22
US13/841,867 US20140113931A1 (en) 2012-06-22 2013-03-15 Substituted picolinamide kinase inhibitors
PCT/US2013/045987 WO2013192046A2 (en) 2012-06-22 2013-06-14 Substituted picolinamide kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201408074VA true SG11201408074VA (en) 2015-01-29

Family

ID=49769665

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408074VA SG11201408074VA (en) 2012-06-22 2013-06-14 Substituted picolinamide kinase inhibitors

Country Status (10)

Country Link
US (1) US20140113931A1 (en)
EP (1) EP2863905A4 (en)
JP (1) JP2015523996A (en)
CN (1) CN104602681A (en)
AU (1) AU2013277473A1 (en)
CA (1) CA2877469A1 (en)
HK (1) HK1209316A1 (en)
IL (1) IL235935A0 (en)
SG (1) SG11201408074VA (en)
WO (1) WO2013192046A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016007111A (en) 2013-12-05 2016-08-11 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase.
MA42623A (en) * 2015-06-02 2018-06-20 Pharmacyclics Llc BRUTON TYROSINE KINASE INHIBITORS
CA3122354A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797706B1 (en) * 1999-06-09 2004-09-28 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclecarboxamide derivative
KR20100132550A (en) * 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
ES2632220T3 (en) * 2009-06-15 2017-09-11 Rigel Pharmaceuticals, Inc. Small molecule tyrosine kinase inhibitors of the spleen (SYK)
US8846928B2 (en) * 2010-11-01 2014-09-30 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
CA2824544A1 (en) * 2011-01-21 2012-07-26 Anil Vasudevan Picolinamide inhibitors of kinases
US9216173B2 (en) * 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors

Also Published As

Publication number Publication date
AU2013277473A1 (en) 2015-02-05
CN104602681A (en) 2015-05-06
HK1209316A1 (en) 2016-04-01
EP2863905A4 (en) 2015-12-16
JP2015523996A (en) 2015-08-20
WO2013192046A2 (en) 2013-12-27
IL235935A0 (en) 2015-01-29
WO2013192046A3 (en) 2014-02-27
US20140113931A1 (en) 2014-04-24
CA2877469A1 (en) 2013-12-27
EP2863905A2 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
SG11201408232RA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805645QA (en) Lsd1 inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201407682TA (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201804309PA (en) Antibody molecules to april and uses thereof
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201407533SA (en) Antiviral compounds
SG11201407981RA (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201407372UA (en) Nampt inhibitors
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201407115XA (en) Carboxylic acid compounds
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization